Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
1.150
+0.070 (6.48%)
At close: Feb 19, 2026, 4:00 PM EST
1.159
+0.009 (0.81%)
After-hours: Feb 19, 2026, 5:17 PM EST
Humacyte Revenue
Humacyte had revenue of $753.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $1.57M.
Revenue (ttm)
$1.57M
Revenue Growth
n/a
P/S Ratio
141.28
Revenue / Employee
$7,141
Employees
220
Market Cap
221.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.57M | 302.00K | 23.91% |
| Dec 31, 2021 | 1.26M | -228.00K | -15.29% |
| Dec 31, 2020 | 1.49M | -4.70M | -75.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 155.10M |
| Arcturus Therapeutics Holdings | 97.60M |
| Alector | 69.05M |
| MediWound | 20.93M |
| Tonix Pharmaceuticals Holding | 10.30M |
| Camp4 Therapeutics | 3.80M |
| Cibus | 3.79M |
| Surrozen | 3.60M |
HUMA News
- 1 day ago - Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting - GlobeNewsWire
- 10 days ago - Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels - GlobeNewsWire
- 6 weeks ago - Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications - GlobeNewsWire
- 6 weeks ago - Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - GlobeNewsWire
- 2 months ago - Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair - GlobeNewsWire
- 2 months ago - Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital - GlobeNewsWire
- 3 months ago - Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results - GlobeNewsWire
- 3 months ago - Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium) - GlobeNewsWire